Isabel Baik PharmD, Arin Jantz PharmD, BCPS, BCTXP, Adina Poparad-Stezar PharmD, BCTXP, Deepak Venkat MD, Nadeen Khoury MD, Milagros Samaniego-Picota MD, Humberto C. Gonzalez MD, Mary Grace Fitzmaurice PharmD, BCTXP
{"title":"评估胰高血糖素样肽-1 受体激动剂在匹配的肾移植和肝移植受者队列中的使用情况","authors":"Isabel Baik PharmD, Arin Jantz PharmD, BCPS, BCTXP, Adina Poparad-Stezar PharmD, BCTXP, Deepak Venkat MD, Nadeen Khoury MD, Milagros Samaniego-Picota MD, Humberto C. Gonzalez MD, Mary Grace Fitzmaurice PharmD, BCTXP","doi":"10.1002/jppr.1953","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Diabetes mellitus (DM) and obesity are common among solid organ transplant recipients, but are associated with an increased risk of graft failure.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for managing both conditions in the general population, there is limited evidence regarding their use among transplant recipients.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>The effect of GLP-1 RAs on post-transplant glucose control (defined as haemoglobin A1c [HbA1c]) among 37 liver and kidney transplant patients was compared to a control cohort. Secondary outcomes included change in total daily insulin requirements and oral DM agents, estimated glomerular filtration rate (eGFR), weight, and body mass index (BMI). Adverse events attributed to GLP-1 RAs, hypoglycaemia, incidence of pancreatitis, biopsy-proven acute rejection, graft loss, and death were assessed. Ethical approval was granted by the Henry Ford Health Institutional Review Board (Reference no: 15959) and the study conforms with the US Federal Policy for the Protection of Human Subjects.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We observed that patients receiving GLP-1 RAs had a median reduction in HbA1c of 0.5% and reduction in insulin and oral anti-DM agents compared to the control group without GLP-1 RAs. There were statistically significant reductions in both weight and BMI in the GLP-1 RA group. Our observed incidence of adverse events was similar to previous literature. Unlike other smaller studies, a decline in eGFR was observed in the GLP-1 RA group. There were no differences in incidence of biopsy-proven acute rejection, graft loss, or death.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>When compared to patients without GLP-1 RA therapy, GLP-1 RAs modestly reduced HbA1c and insulin requirements and statistically reduced weight/BMI review at 6 months. GLP-1 RAs, even if initiated early post-transplant, were seemingly safe and effective. Larger, prospective studies are warranted to evaluate the safety and efficacy of GLP-1 RAs in this population.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"55 2","pages":"110-116"},"PeriodicalIF":1.0000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating the use of glucagon-like peptide-1 receptor agonists in a matched cohort of kidney and liver transplant recipients\",\"authors\":\"Isabel Baik PharmD, Arin Jantz PharmD, BCPS, BCTXP, Adina Poparad-Stezar PharmD, BCTXP, Deepak Venkat MD, Nadeen Khoury MD, Milagros Samaniego-Picota MD, Humberto C. Gonzalez MD, Mary Grace Fitzmaurice PharmD, BCTXP\",\"doi\":\"10.1002/jppr.1953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Diabetes mellitus (DM) and obesity are common among solid organ transplant recipients, but are associated with an increased risk of graft failure.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for managing both conditions in the general population, there is limited evidence regarding their use among transplant recipients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>The effect of GLP-1 RAs on post-transplant glucose control (defined as haemoglobin A1c [HbA1c]) among 37 liver and kidney transplant patients was compared to a control cohort. Secondary outcomes included change in total daily insulin requirements and oral DM agents, estimated glomerular filtration rate (eGFR), weight, and body mass index (BMI). Adverse events attributed to GLP-1 RAs, hypoglycaemia, incidence of pancreatitis, biopsy-proven acute rejection, graft loss, and death were assessed. Ethical approval was granted by the Henry Ford Health Institutional Review Board (Reference no: 15959) and the study conforms with the US Federal Policy for the Protection of Human Subjects.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We observed that patients receiving GLP-1 RAs had a median reduction in HbA1c of 0.5% and reduction in insulin and oral anti-DM agents compared to the control group without GLP-1 RAs. There were statistically significant reductions in both weight and BMI in the GLP-1 RA group. Our observed incidence of adverse events was similar to previous literature. Unlike other smaller studies, a decline in eGFR was observed in the GLP-1 RA group. There were no differences in incidence of biopsy-proven acute rejection, graft loss, or death.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>When compared to patients without GLP-1 RA therapy, GLP-1 RAs modestly reduced HbA1c and insulin requirements and statistically reduced weight/BMI review at 6 months. GLP-1 RAs, even if initiated early post-transplant, were seemingly safe and effective. Larger, prospective studies are warranted to evaluate the safety and efficacy of GLP-1 RAs in this population.</p>\\n </section>\\n </div>\",\"PeriodicalId\":16795,\"journal\":{\"name\":\"Journal of Pharmacy Practice and Research\",\"volume\":\"55 2\",\"pages\":\"110-116\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Practice and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1953\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1953","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Evaluating the use of glucagon-like peptide-1 receptor agonists in a matched cohort of kidney and liver transplant recipients
Background
Diabetes mellitus (DM) and obesity are common among solid organ transplant recipients, but are associated with an increased risk of graft failure.
Aim
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for managing both conditions in the general population, there is limited evidence regarding their use among transplant recipients.
Method
The effect of GLP-1 RAs on post-transplant glucose control (defined as haemoglobin A1c [HbA1c]) among 37 liver and kidney transplant patients was compared to a control cohort. Secondary outcomes included change in total daily insulin requirements and oral DM agents, estimated glomerular filtration rate (eGFR), weight, and body mass index (BMI). Adverse events attributed to GLP-1 RAs, hypoglycaemia, incidence of pancreatitis, biopsy-proven acute rejection, graft loss, and death were assessed. Ethical approval was granted by the Henry Ford Health Institutional Review Board (Reference no: 15959) and the study conforms with the US Federal Policy for the Protection of Human Subjects.
Results
We observed that patients receiving GLP-1 RAs had a median reduction in HbA1c of 0.5% and reduction in insulin and oral anti-DM agents compared to the control group without GLP-1 RAs. There were statistically significant reductions in both weight and BMI in the GLP-1 RA group. Our observed incidence of adverse events was similar to previous literature. Unlike other smaller studies, a decline in eGFR was observed in the GLP-1 RA group. There were no differences in incidence of biopsy-proven acute rejection, graft loss, or death.
Conclusion
When compared to patients without GLP-1 RA therapy, GLP-1 RAs modestly reduced HbA1c and insulin requirements and statistically reduced weight/BMI review at 6 months. GLP-1 RAs, even if initiated early post-transplant, were seemingly safe and effective. Larger, prospective studies are warranted to evaluate the safety and efficacy of GLP-1 RAs in this population.
期刊介绍：
The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
